(0.01%) 5 332.50 points
(0.00%) 39 945 points
(-0.06%) 18 751 points
(-1.87%) $78.31
(-1.45%) $2.71
(-0.42%) $2 428.20
(-1.24%) $32.03
(-0.90%) $1 054.10
(-0.01%) $0.921
(-0.34%) $10.66
(-0.05%) $0.787
(-0.10%) $90.58
-1.02% $ 1.940
@ $2.43
Emitido: 12 feb 2024 @ 15:26
Retorno: -20.16%
Señal anterior: feb 6 - 14:26
Señal anterior:
Retorno: 0.00 %
Live Chart Being Loaded With Signals
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States...
Stats | |
---|---|
Volumen de hoy | 29 281.00 |
Volumen promedio | 1.48M |
Capitalización de mercado | 5.54M |
EPS | $0 ( 2024-05-20 ) |
Próxima fecha de ganancias | ( $-0.980 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.230 |
ATR14 | $0.0120 (0.62%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-01 | Young David | Buy | 1 675 | Common Stock |
2024-01-01 | Young David | Sell | 518 | Common Stock |
2024-01-01 | Young David | Sell | 1 675 | Restricted Stock Units |
2024-01-01 | Stanker James H | Sell | 1 675 | Restricted Stock Units |
2024-01-01 | Stanker James H | Buy | 1 675 | Common Stock |
INSIDER POWER |
---|
80.51 |
Last 99 transactions |
Buy: 3 005 145 | Sell: 402 801 |
Volumen Correlación
Processa Pharmaceuticals, Correlación
10 Correlaciones Más Positivas | |
---|---|
VTNR | 0.928 |
UXIN | 0.926 |
VRM | 0.924 |
PLL | 0.92 |
AXDX | 0.912 |
RNAZ | 0.91 |
CNSP | 0.904 |
MHUA | 0.897 |
IRBT | 0.896 |
SNAX | 0.893 |
10 Correlaciones Más Negativas | |
---|---|
FFNW | -0.912 |
HQY | -0.886 |
ADTH | -0.881 |
SFBC | -0.875 |
FGFPP | -0.867 |
ISRG | -0.859 |
AGNCP | -0.854 |
FSEA | -0.849 |
PRAX | -0.847 |
SRPT | -0.845 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Processa Pharmaceuticals, Correlación - Moneda/Commodity
Processa Pharmaceuticals, Finanzas
Annual | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-222.00 (0.00 %) |
EPS: | $-0.850 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-222.00 (0.00 %) |
EPS: | $-0.850 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-27.53M (0.00 %) |
EPS: | $-68.10 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.750 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Processa Pharmaceuticals,
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico